ID Source | ID |
---|---|
PubMed CID | 111295 |
CHEMBL ID | 2336907 |
SCHEMBL ID | 6248471 |
MeSH ID | M0095735 |
Synonym |
---|
acetylphenylalanamide |
(2s)-2-acetamido-3-phenylpropanamide |
7376-90-1 |
benzenepropanamide, alpha-(acetylamino)-, (s)- |
CHEMBL2336907 |
ac-phe-nh2 |
DTXSID10224114 |
n-alpha-acetyl-l-phenylalanine amide |
mfcd00080840 |
AKOS024259128 |
SCHEMBL6248471 |
acetyl-l-phenylalanine amide |
acetyl-l-phenylalaninamid |
n-acetyl-l-phenylalanine amide |
(s)-2-acetamido-3-phenylpropanamide |
ac phe-nh2 |
F11015 |
AS-46952 |
ac-phe nh2 |
ac phe nh2 |
n-acetylphenylalanyl-amide; (s)-2-acetamido-3-phenylpropanamide |
ac-l-phe-nh2 |
benzenepropanamide,a-(acetylamino)-,(as)- |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID734191 | Inhibition of UBR protein in rabbit reticulocyte lysates assessed as inhibition of Tyr-nsP4 substrate degradation at 2 mM | 2013 | Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6 | Development and characterization of monomeric N-end rule inhibitors through in vitro model substrates. |
AID734192 | Inhibition of UBR protein in rabbit reticulocyte lysates assessed as inhibition of Tyr-nsP4 substrate degradation at 2 mM by immunoblotting analysis in presence of bestatin | 2013 | Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6 | Development and characterization of monomeric N-end rule inhibitors through in vitro model substrates. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |